{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:18Z","timestamp":1787785578023,"version":"build-2784847793"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Multiple endocrine neoplasia type 2 syndrome (MEN2) is a hereditary disease resulting from mutations of the rearranged during transfection (RET) protooncogene subclassified into MEN2A [medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism] and MEN2B (MTC, pheochromocytoma, Marfanoid habitus, mucous neuromas, and intestinal ganglioneuromatosis). Prophylactic thyroidectomy is recommended in RET-mutated patients. The age at which it should be performed depends on the type and aggressiveness of the mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim of the study<\/jats:title><jats:p>This study aimed to evaluate the genotype\/phenotype correlation and outcome in pediatric\/adolescent carriers of MEN2 RET mutation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>In a retrospective series of 23 carriers of RET MEN2 mutation who were \u226419 years old at diagnosis and had undergone total thyroidectomy \u00b1 lymphadenectomy, the following were analyzed: 1) specific RET mutation, 2) clinical and histopathological characteristics, 3) genotype\/phenotype correlation, and 4) outcome at last follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our series, the female gender was more prevalent (F\/M ratio 2.8\/1), and the median age was 14.9 years [interquartile range (IQR) 12.6\u201317.2]. RET mutations were at very high risk in 4.3% of patients (M918T), high risk in 43.5% (C634), and moderate risk in 52.2% (47.8% C618 and 4.3% C620). All patients underwent surgery: at histology, MTC was found in 19\/23 (82.6%) patients, C-cell hyperplasia in 2\/23 (8.7%), and benign histology in 2\/23 (8.7%). Ten patients (52.6%) had a disease event during the follow-up: 2\/19 (10.5%) showed biochemical disease, 6\/19 (31.6%) lymph node recurrences, and 2\/19 (10.5%) distant metastases (50% liver, 50% bone). At the last follow-up, nine MTCs were not cured. One patient died after 9 years of follow-up at 21 years old (M918T RET+).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>From these data, it is clear to see the importance of genetic counseling and RET screening in all first-degree relatives of patients with proven MEN2. The goal should be to subject patients to surgery for prophylactic and not curative purposes, i.e., before the onset of MTC, given the high risk of persistent or recurrent disease also in pediatric\/adolescent patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1464890","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:31:53Z","timestamp":1736227913000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Medullary thyroid cancer in MEN2 pediatric\/adolescent carriers of RET mutation: genotype\/phenotype correlation and outcome in a retrospective series of 23 patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Guenda","family":"Di Benedetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Barca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Scollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenza","family":"Gian\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Martorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pellegriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Sapuppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00027-9","article-title":"Thyroid cancer incidence trends by histology in 25 countries: a population-based study","volume":"9","author":"Miranda-Filho","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197308302890901","article-title":"C-cell hyperplasia preceding medullary thyroid carcinoma","volume":"289","author":"Wolfe Hubert","year":"1973","journal-title":"New Engl J Med"},{"key":"B4","volume-title":"Cancer of the Thyroid Invasive: Trends in SEER Incidence and U.S. Mortality Using the Joinpoint Regression Program, 1975\u20132011(SEER) Stat version 8.1.2 Rate Session. (Access the SEER 18 database at www.seer.cancer.gov). Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 596 WELLS ET AL. 2012 Sub (2000\u20132010) < Katrina\/Rita Population Adjustment > - Linked To County Attributes - Total U.S., 1969\u2013 2011 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission","year":"2012"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0040","article-title":"Medullary carcinoma","volume":"8","author":"Tuttle","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1234","article-title":"Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d\u2019Etude des Tumeurs Endocrines","volume":"96","author":"Rohmer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2003.07.019","article-title":"When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations","volume":"134","author":"Niccoli-Sire","year":"2003","journal-title":"Surgery"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1836","article-title":"Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level","volume":"90","author":"MachensA","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","unstructured":"The immediate upstream sequence of the mouse Ret gene controls tissue-specific expression in transgenic mice\n          \n          \n            \n              Zordan\n              P\n            \n            \n              Tavella\n              S\n            \n            \n              Brizzolara\n              A\n            \n            \n              Biticchi\n              R\n            \n            \n              Ceccherini\n              I\n            \n            \n              Garofalo\n              S\n            \n          \n          10.3892\/ijmm.18.4.601\n          \n          2006"},{"key":"B11","article-title":"Childhood multiple endocrine neoplasia (MEN) syndromes treatment (PDQ\u00ae): health professional version","volume-title":"PDQ Cancer Information Summaries","year":"2002"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043999","article-title":"Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A","volume":"353","author":"Skinner","year":"2005","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-7404(03)00033-1","article-title":"Management of hereditary thyroid cancer in children","volume":"12","author":"Skinner","year":"2003","journal-title":"Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-821209","article-title":"Management of patients with hereditary medullary thyroid carcinoma","volume":"14","author":"Fitze","year":"2004","journal-title":"Eur J Pediatr Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02394.x","article-title":"Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations","volume":"63","author":"Learoyd","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid carcinoma, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10228","article-title":"Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell Malignant disease in asymptomatic carriers","volume":"94","author":"Sanso","year":"2002","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes (Basel)"},{"key":"B19","article-title":"Co-existence of papillary and medullary thyroid carcinoma: reports of three cases","volume":"32","author":"Calapkulu","year":"2022","journal-title":"J Coll Physicians Surg Pak"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03622.x","article-title":"Concurrent occurrence of medullary thyroid carcinoma and papillary thyroid carcinoma in the same thyroid should be considered as coincidental","volume":"72","author":"Kim","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021713","article-title":"Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer","volume":"88","author":"Scollo","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1998.00392.x","article-title":"Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d\u2019\u00e9tude des tumeurs \u00e0 calcitonine","volume":"48","author":"Modigliani","year":"1998","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1464890\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:31:57Z","timestamp":1736227917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1464890\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":22,"alternative-id":["10.3389\/fonc.2024.1464890"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1464890","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1464890"}}